CIK 0001781174 · <br>Emerging growth company
Acrivon Therapeutics, Inc.
Sign in to watch- Ticker
- ACRV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 825125532
- Phone
- 617-207-8979
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $38,534
- in 8 filings
Net −$38,534. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blume-Jensen Peter −$34K President and CEO sold <1% of stake
- Miller Mary −$2K Chief Legal Officer sold 1% of stake
- Devroe Eric −$1K Chief Operating Officer sold <1% of stake
- Gamelin Erick −$804 Chief Development Officer sold <1% of stake
- Peterson Katharine −$203 Chief Accounting Officer sold <1% of stake
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-01 | Levy Adam D. Chief Financial Officer | Shares withheld for taxes | −1,164 | $1.26 | $1K | 12,151 |
| 2025-07-17 | Miller Mary Chief Legal Officer | Shares withheld for taxes | −558 | $1.32 | $737 | 35,765 |
| 2025-06-13 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2025-06-13 | DiRocco Derek Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2025-06-13 | TOMSICEK MICHAEL JOHN Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2025-06-13 | Shacham Sharon Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2025-06-13 | Palani Santhosh Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2025-06-13 | Magovcevic-Liebisch Ivana Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2025-06-13 | BAUM CHARLES M Director | Grant or award · Stock Option (Right to Buy) | +20,275 | 20,275 | ||
| 2025-05-21 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −19,904 | $1.15 | $23K | 2,206,111 |
| 2025-05-14 | Peterson Katharine Chief Accounting Officer | Shares withheld for taxes | −99 | $1.14 | $113 | 4,320 |
| 2025-05-14 | Miller Mary Chief Legal Officer | Shares withheld for taxes | −184 | $1.14 | $210 | 36,323 |
| 2025-05-14 | Gamelin Erick Chief Development Officer | Shares withheld for taxes | −403 | $1.14 | $459 | 16,089 |
| 2025-05-14 | Devroe Eric Chief Operating Officer | Shares withheld for taxes | −613 | $1.14 | $699 | 66,534 |
| 2025-05-14 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −59,766 | $1.14 | $68K | 2,226,015 |
| 2025-05-14 | Blume-Jensen Peter President and CEO | Shares withheld for taxes | −491 | $1.14 | $560 | 315,686 |
| 2025-05-01 | PERCEPTIVE ADVISORS LLC 10% owner | Sale | −298,886 | $1.34 | $401K | 3,104,139 |
| 2025-04-30 | PERCEPTIVE ADVISORS LLC 10% owner | Sale | −437,881 | $1.41 | $617K | 3,403,025 |
| 2025-04-29 | PERCEPTIVE ADVISORS LLC 10% owner | Sale | −250,000 | $1.41 | $353K | 3,840,906 |
| 2025-04-28 | PERCEPTIVE ADVISORS LLC 10% owner | Sale | −215,283 | $1.56 | $336K | 4,090,906 |
Page 5 of 6 · 113 trades